Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$48.11
$0.01(0.04%)
At close: 4:00 PM EST
$48.11
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$14.79 - $48.53
Previous CloseN/A
Volume37.78K
Average Volume (3M)1.53M
Market Cap
$2.58B
Enterprise Value$2.44B
Total Cash (Recent Filing)$462.62M
Total Debt (Recent Filing)$399.00K
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 20, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding60,895,008
10 Day Avg. Volume1,399,980
30 Day Avg. Volume1,525,868
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.98K
Enterprise Value/Ebitda-21.29
Forecast
1Y Price Target
$50.00Price Target Upside3.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$10.00K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Pretreated PatientsPhase 1b data show meaningful and durable molecular responses in heavily pretreated chronic myeloid leukemia patients, supporting ELVN-001's clinical promise in later treatment lines.
Differentiated Mechanism And PositioningThe lead candidate targets a different binding pocket than existing therapies, enabling treatment of patients who progressed on allosteric inhibitors and supporting a distinct role in second-line and later therapy.
M&A InterestA major pharmaceutical acquisition in the chronic myeloid leukemia space validates industry interest in differentiated therapies and increases the likelihood that Enliven could become an acquisition target.
Bears Say
Cash Runway And Financing RiskLimited cash relative to burn raises the likelihood of future financing needs that could dilute shareholders or delay development milestones.
Competitive Benchmark PressureA competing BCR::ABL1 inhibitor reported higher early response rates, setting a tougher benchmark that could constrain ELVN-001's commercial uptake and valuation.
Data Maturity And Outcome UncertaintyImmature early-stage response analyses can be biased while many patients remain unevaluable, leaving uncertainty around definitive effectiveness for ELVN-001.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $48.53 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $2.58B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 20 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.095.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.44.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 60,895,008 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went up 4.278%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (3.93% Upside)
$50.00 (3.93% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $295.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
191.04%
12-Months-Change
Fundamentals
Return on Equity
-24.22%
Trailing 12-Months
Asset Growth
46.20%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$50.00
▲(3.93% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―
Ownership Overview
16.37% Insiders
18.25% Mutual Funds
1.38% Other Institutional Investors
54.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---